Jump to content
Main menu
Main menu
move to sidebar
hide
Navigation
Main page
News Log
Topics
Nordics
AI Docs
Soft Funding
Investors
AIDAVA
Research Wiki
Search
Search
Create account
Log in
Personal tools
Create account
Log in
Pages for logged out editors
learn more
Contributions
Talk
Editing
Pharmasum Therapeutics
Page
Discussion
English
Read
Edit
View history
Tools
Tools
move to sidebar
hide
Actions
Read
Edit
View history
General
What links here
Related changes
Special pages
Page information
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
{{DISPLAYTITLE:Pharmasum Therapeutics}} {{Infobox company | name = Pharmasum Therapeutics AS | org_number = 913746430 | founded = 2014-06-02 | employees = Not disclosed | address = Norway | industry = 72.100 β Biotechnology research | website = https://www.pharmasum.com | nht_category = Startup | description = Pharmasum Therapeutics is developing drugs for dementia. Dementia is a group of neurodegenerative diseases causing gradual loss of brain function β memory, cognition, daily activities. Pharmasum is addressing one of the largest unmet healthcare challenges of today. | notes = No disclosed revenue, funding, or employees. Founded 2014. Dementia drug development is extremely high-risk/high-reward. | related_companies = [[Hemispherian]], [[Exact Therapeutics]], [[Nextera]], [[Nordic Brain Tech]], [[Norway Health Tech]] | categories = Norway Health Tech, Startups, Biotechnology, Drug Development, Neurology | sources = https://www.pharmasum.com; https://data.brreg.no/enhetsregisteret/api/enheter/913746430 }} == About == Pharmasum Therapeutics AS is a Norwegian biotechnology company developing drugs for the treatment of dementia. Founded in 2014. == Focus Area == Dementia is characterized by a group of neurodegenerative diseases leading to gradual loss of brain function, including: * Memory loss * Cognitive decline * Loss of daily living activities Pharmasum describes dementia as one of the largest unmet healthcare challenges of today. == Market == Dementia affects approximately 55 million people globally, with the World Health Organization projecting this number to triple by 2050. Alzheimer's disease is the most common form. The field has seen significant recent investment and regulatory activity (Lecanemab, Donanemab approvals), but substantial unmet need remains. == Research Status == At the time of this research, limited public information was available about Pharmasum's specific technology or pipeline stage. == References == <references/> [[Category:Norway Health Tech]] [[Category:Startups]] [[Category:Biotechnology]] [[Category:Drug Development]] [[Category:Neurology]]
Summary:
Please note that all contributions to Research Wiki may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Research Wiki:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Template used on this page:
Template:Infobox company
(
edit
)
Toggle limited content width